The effects of olprinone, a phosphodiesterase 3 inhibitor, on systemic and cerebral circulation

Current Vascular Pharmacology

Volumn 4, Issue 1, 2006, Pages 1-7

  Ueda, Takashi ^a   Mizushige, Katsufumi ^a  

^a National Hospital Organization   (Japan)

Author keywords

Arterial distensibility; Bronchodilator; Cardiac function; Cerebral circulation; Olprinone; Phosphodiesterase 3 inhibitor; Renal function; Splanchnic circulation

Indexed keywords

AMRINONE; CALCIUM ION; CAPTOPRIL; CILOSTAZOL; CYCLIC AMP; CYSTEINE ETHYL ESTER TC 99M; DOBUTAMINE; INDOMETACIN; LOPRINONE; MILRINONE; PHOSPHODIESTERASE III; PROPRANOLOL; SALBUTAMOL; IMIDAZOLE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PYRIDONE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTERIAL PRESSURE; ARTERY COMPLIANCE; ASTHMA; BRAIN ARTERY; BRAIN BLOOD FLOW; BRAIN CIRCULATION; BRAIN CORTEX; CALCIUM TRANSPORT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; ENZYME INHIBITION; ENZYME LOCALIZATION; HEART CONTRACTION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTILITY; HEART MUSCLE CELL; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMMUNE SYSTEM; KIDNEY FUNCTION; LONG TERM CARE; LOW DRUG DOSE; LUNG ARTERY PRESSURE; MONOTHERAPY; NONHUMAN; OXYGEN SUPPLY; RADIAL ARTERY; RESPIRATORY SYSTEM; REVIEW; SMOOTH MUSCLE FIBER; SPLANCHNIC BLOOD FLOW; STROKE; SUBARACHNOID HEMORRHAGE; SYSTEMIC CIRCULATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VASCULAR SMOOTH MUSCLE; VASODILATATION; ADULT; BRONCHOSPASM; HEART RATE;

ADULT; BRONCHOCONSTRICTION; CEREBROVASCULAR CIRCULATION; HEART RATE; HUMANS; IMIDAZOLES; MILRINONE; MUSCLE, SMOOTH, VASCULAR; MYOCARDIAL CONTRACTION; PHOSPHODIESTERASE INHIBITORS; PYRIDONES; SPLANCHNIC CIRCULATION;

EID: 33644863442     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106775203072     Document Type: Review

References (72)

1. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Eng J Med 1993; 329: 149-55.
2. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Eng J Med 1982; 307: 205-11.
3. Feldman MD, Copelas L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ, et al. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987; 75: 331-9.
4. Takaoka H, Takeuchi M, Odake M, Hayashi Y, Mori M, Hata K, et al. Comparison of the effects on arterial-ventricular coupling between phosphodiesterase inhibitor and dobutamine in the diseases human heart. J Am Coll Cardiol 1993; 22: 598-606.
5. Sugioka M, Ito M, Masuoka H, Ichikawa K, Konishi T, Tanaka T, et al. Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the effects of new cardiotonic agents on these isoenzymes. Naunyn Schmiedebergs Arch Pharmacol 1994; 350: 284-93.
6. Alousi AA, Stankus GP, Stuart JC, Walton LH. Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species. J Cardiovasc Pharmacol 1983; 5: 804-11.
7. Ogawa T, Ohhara H, Tsunoda H, Kuroki J, Shoji T. Cardiovascular effects of the new cardiotonic agent 1, 2-dihydro-6-methyl-2-oxo-5-(imidazo[1,2-a] pyridin-6-yl)-3-pyridine carbonitrile hydrochloride monohydrate: first communication: studies on isolated guinea pig cardiac muscles. Arzneimittelforschung 1989; 39: 33-7.
8. Endoh M, Yamashita S, Taira N. positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. J Pharmacol Exp Ther 1982; 221: 775-83.
9. Satoh H, Endoh M. Effects of a new cardiotonic agent 1, 2-dihydro-6-methyl-2-oxo-5- [imidazo(1,2-a)pyridin-6-yl]-3-pyridine carbonitrile hydrochloride monohydrate (E-1020) on contractile force and cyclic AMP metabolism in canine ventricular muscle. Jpn J Pharmacol 1990; 52: 215-24.
10. Mizushige K, Ueda T, Yukiiri K, Suzuki H. Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vosodilator effects. Cardiovasc Drug Rev 2002; 20: 163-74.
11. Kawamura A, Yoshikawa T, Takahashi T, Hayashi T, Takahashi E, Anzai T, et al. Randomized trial of phosphodiesterase inhibitors versus catecholamines in patients with acutely decompensated heart failure. Jpn Circ J 2001; 65: 858-62.
12. Orime Y, Shiono M, Hata H, Yagi S, Tsukamoto S, Okumura H, et al. Effects of phosphodiesterase inhibitors after coronary artery bypass grafting. Jpn Circ J 1999; 63: 117-22.
13. Baim DS, McDowell AV, Cherniles J, Monrad ES, Parker JA, Edelson J, et al. Evaluation of a new bipyridine inotropic agent-milrinone-in patients with severe congestive heart failure. N Eng J Med 1983; 309: 748-56.
14. Simonton CA, Chatterjee K, Cody RJ, Kubo SH, Leonard D, Daly P, et al. Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. J Am Coll Cardiol 1985; 6: 453-9.
15. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Eng J Med 1991; 325: 1468-75.
16. Packer M. Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. Am J Cardiol 1989; 63: 41-5.
17. Murakami R, Sano K, Murakami Y, Shimada T, Morioka S. Effects of intracoronary infusion of an inotropic agent, E-1020 (loprinone hydrochloride), on cardiac function: evaluation of left ventricular contractile performance using the end-systolic pressure-volume relationship. Int J Cardiol 1995; 51: 57-63.
18. Suga H, Sagawa K. Instantaneous pressure-volume relationships and their ratio in the excised, supported canine left ventricle. Circ Res 1974; 35: 117-26.
19. Suga H, Sagawa K, Shoukas AA. Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circ Res 1973; 32: 314-22.
20. Baan J, van der Velde ET, de Bruin HG, Smeenk GJ, Koops J, van Dijk AD, et al. Continuous measurement of left ventricular volume in animals and humans by conductance catheter. Circulation 1984; 70: 812-23.
21. Ludmer PL, Wright RF, Arnold JM, Ganz P, Braunwald E, Colucci WS. Separation of the direct myocardial and vasodilator actions of milrinone administrated by an intracoronary infusion technique. Circulation 1986; 73: 130-7.
22. Sunagawa K, Maughan WL, Burkhoff D, Sagawa K. Left ventricular interaction with arterial lord studied in isolated canine ventricle. Am J Physiol 1983; 245: H773-80.
23. Sunagawa K, Maughan WL, Sagawa K. Optimal arterial resistance for the maximal stroke work studied in isolated canine left ventricle. Circ Res 1985; 56: 586-95.
24. Sunagawa K, Maughan WL, Sagawa K. Stroke volume effect of changing arterial input impedance over selected frequency ranges. Am J Physiol 1985; 248: H477-84.
25. Burkhoff D, Sagawa K. Ventricular efficiency predicted by an analytical model. Am J Physiol 1986; 250: R1021-7.
26. Barenbrock M, Spieker C, Witta J, Evers S, Hoeks AP, Rahn KH, et al. Reduced distensibility of the common carotid artery in patients treated with ergotamine. Hypertension 1996; 28: 115-9.
27. Dobrin PB, Rovick AA. Influence of vascular smooth muscle on contractile mechanics and elasticity of arteries. Am J Physiol 1969; 217: 1644-51.
28. Seki M, Mizushige K, Ueda T, Kitadai M, Matsuo H. Effect of olprinone, a phosphodiesterase III inhibitor, on arterial wall distensibility: differentiation between aorta and common carotid artery. Heart Vessels 1999; 14: 224-31.
29. Hayashi K, Handa H, Nagasawa S, Okumura A, Moritake K. Stiffness and elastic behavior of human intracranial and extracranial arteries. J Biomech 1980; 13: 175-84.
30. Kawasaki T, Sasayama S, Yagi S, Asakawa T, Hirai T. Non-invasive assessment of the age related changes in stiffness of major branches of the human arteries. Cardiovasc Res 1987; 21: 678-87.
31. Ahlgren ÅR, Hansen F, Sonesson B, Lanne T. Stiffness and diameter of the common carotid artery and abdominal aorta in women. Ultrasound Med Biol 1997; 23: 983-8.
32. Länne T, Hansen F, Mangell P, Sonesson B. Differences in mechanical properties of the common carotid artery and abdominal aorta in healthy males. J Vasc Surg 1994; 20: 219-25.
33. Wada T, Fujishiro K, Fukumoto T, Yamazaki S. Relationship between ultrasound assessment of arterial wall properties and blood pressure. Angiology 1997; 48: 893-900.
34. Safer ME, Simon AC, Levenson JA, Sazor JL. Hemodynamic effects of diltiazem in hypertension. Circ Res 1983; 52 (Suppl I), II69-73.
35. Fischer GM, Llaurado JG. Collagen and elastin content in canine arteries selected from functionally different vascular beds. Circ Res 1966; 19: 394-9.
36. Fujimoto S, Ohashi M, Hiramoto A, Inoue Y, Nagai K, Shiokawa H, et al. Vasorelaxant effect of olprinone, an inhibitor of phosphodiesterase 3, on mesenteric small artery and vein of rabbits. Eur J Pharmacol 1998; 353: 239-46.
37. Harris AL, Grant AM, Silver PJ, Evans DB, Alousi AA. Differential vasorelaxant effects of milrinone and amrinone on contractile responses of canine coronary, cerebral, and renal arteries. J Cardiovasc Pharmacol 1989; 13: 238-44.
38. Fujimura M, Kamio Y, Myou T, Hashimoto T, Matsuda T. Effect of a phosphodiesterase 3 inhibitor, cilostazol, on bronchial hyperresposiveness in elderly patients with asthma. Int Arch Allergy Immunol 1997; 114: 379-84.
39. Bardin PG, Dorward MA, Lampe FC, Franke B, Holgate ST. Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen. Br J Clin Pharmacol 1998; 45: 387-91.
40. Fujimura M, Kamio Y, Saito M, Hashimoto T, Matsuda T. Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo. Am J Respir Crit Care Med 1995; 151: 222-5.
41. Myou S, Fujimura M, Kamio Y, Ishiura Y, Tachibana H, Hirose T, et al. Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 817-20.
42. Hu H, Takata M, Kusakawa I, Fujita M, Miyasaka K. Intratracheal administration of phosphodiesterase III inhibitor attenuates bronchoconstriction in cats: a preliminary report. Pediatr Pulmonol 1995; 19: 360-4.
43. Rabe KF, Tenor H, Dent G, Schudt C, Liebig S, Magnussen H. Phosphodiesterase isoenzymes modulating inherent tone in human airways: identification and characterization. Am J Physiol 1993; 264: L458-64.
44. de Boer J, Philpott AJ, van Amsterdam RG, Shahid M, Zaagsma H, Nicholson CD. Human bronchial cyclic nucleotide phosphodiesterase isozymes: biochemical and pharmacological analysis using selective inhibitors. Br J Pharmacol 1992; 106: 1028-34.
45. Edmunds LH Jr. Pulseless cardiopulmonary bypass. J Thorac Cardiovasc Surg 1982; 84: 800-4.
46. Leitman IM, Paull DE, Barie PS, Isom OW, Shires GT. Intraabdominal complications of cardiopulmonary bypass operations. Surg Gynecol Obstet 1987; 165: 251-4.
47. Heikkinen LO, Ala-Kulju KV. Abdominal complications following cardiopulmonary bypass in open-heart surgery. Scand J Thorac Cardiovasc Surg 1987; 21: 1-7.
48. Collins JD, Bassendine MF, Ferner R, Blesovsky A, Murray A, Pearson DT, et al. Incidence and prognostic importance of jaundice after cardiopulmonary bypass surgery. Lancet 1983; I: 1119-23.
49. Takahashi T, Kunimoto F, Ichikawa H, Ishikawa S, Sato Y, Hasegawa Y, et al. Gastric intramucosal pH and hepatic venous oximetry after cardiopulmonary bypass in valve replacement patients. Cardiovasc Surg 1996; 4: 308-10.
50. Doglio GR, Pusajo JF, Egurrola MA, Bonfigli GC, Parra C, Vetere L, et al. Gastric mucosal pH as a prognostic index of mortality in critically ill patients. Crit Care Med 1991; 19: 1037-40.
51. Yamaura K, Akiyoshi K, Irita K, Taniyama T, Takahashi S. Effects of olprinone, a new phosphodiesterase inhibitor, on gastric intramucosal acidosis and systemic inflammatory responses following hypothermic cardiopulmonary bypass. Acta Anaesthesiol Scand 2001; 45: 427-34.
52. Iribe G, Yamada H, Matsunaga A, Yoshimura N. Effects of the phosphodiesterase III inhibitors olprinone, milrinone, and amrinone on hepatosplanchnic oxygen metabolism. Crit Care Med 2000; 28: 743-8.
53. Fitzpatrick PG, Cinquegrani MP, Vakiener AR, Baggs JG, Biddle TL, Liang CS, et al. Hemodynamic and regional blood flow response to milrinone in patients with severe congestive heart failure. a dose ranging study. Am Heart J 1987; 114: 97-105.
54. Möllhoff T, Loick HM, Van Aken H, Schmidt C, Rolf N, Tjan TD, et al. Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB). Anesthesiology 1999; 90: 72-80.
55. LeJemtel TH, Maskin CS, Mancini D, Sinoway L, Feld H, Chadwick B. Systemic and regional hemodynamic effects of captopril and milrinone administrated alone and concomitantly in patients with heart failure. Circulation 1985; 72: 364-9.
56. Kanda M, Yasuda S, Goto Y, Sumida H, Baba T, Noguchi T, et al. Diuretic effect of phosphodiesterase inhibitors depends on baseline renal function in patients with congestive heart failure. Am J Cardiol 1999; 83: 1274-7.
57. Acar C, Jebara VA, Portoghese M, Beyssen B, Pagny JY, Grare P, et al. Revival of the radial artery for coronary artery bypass grafting. Ann Thorac Surg 1992; 54: 659-60.
58. Adachi H, Kamata S, Kodama K, Nagakura T. Vasorelaxant effect of a phosphodiesterase 3 inhibitor, olprinone, on isolated human radial artery. Eur J Parmacol 2000; 396: 43-7.
59. Yu Y, Mizushige K, Ueda T, Nishiyama Y, Seki M, Aoyama T, et al. Effect of olprinone, phosphodiesterase III inhibitor, on cerebral blood flow assessed with technetium-99m-ECD SPECT. J Cardiovasc Pharmacol 2000; 35: 422-6.
60. Yukiiri K, Mizushige K, Ueda T, Nishiyama Y, Aoyama T, Kohno M. Effects of olprinone, a phosphodiesterase 3 inhibitor, on regional cerebral blood flow of cerebral cortex in stroke patients. J Cardiovasc Pharmacol 2001; 37: 375-80.
61. Nakane H, Ibayashi S, Fujii K, Sadoshima S, Irie K, Kitazono T, et al. Cerebral blood flow and metabolism in patients with silent brain infarction: occult misery perfusion in the cerebral cortex. J Neurol Neurosurg Psychiatry 1998; 65: 317-21.
62. Kobayashi S, Okada K, Yamashita K. Incidence of silent lacunar lesion in normal adults and its relation to cerebral blood flow and risk factors. Stroke 1991; 22: 1379-83.
63. i and force in middle cerebral artery of the rabbit. Br J Pharmacol 1998; 123: 869-78.
64. Sato K, Yoshimoto T. Effects of olprinone on systemic and cerebral circulation in patients with subarachnoid hemorrhage. J Neurosurg Anesthesiol 2000; 12: 81-3.
65. Khajavi K, Ayzman I, Shearer D, Jones SC, Levy JH, Prayson RA, et al. Prevention of chronic cerebral vasospasm in dogs with milrinone. Neurosurgery 1997; 40: 354-63.
66. Onoue H, Katusic Z. The effect of subarachnoid hemorrhage on mechanisms of vasodilation mediated by cyclic adenosine monophosphate. J Neurosurg 1998; 89: 111-7.
67. Yoshida K, Watanabe H, Nakamura S. Intraarterial injection of amrinone for vasospasm induced by subarachnoid hemorrhage. Am J Neuroradiol 1997; 18: 492-6.
68. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest 1985; 75: 643-9.
69. Banner KH, Moriggi E, Da Ros B, Schioppacassi G, Semeraro C, Page CP. The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation. Br J Pharmacol 1996; 119: 1255-61.
70. Schudt C, Tenor H, Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J 1995; 8: 1179-83.
71. Jeremy JY, Gill J, Mikhailidis D. Effect of milrinone on thromboxane A2 synthesis, cAMP phosphodiesterase and 45Ca2+ uptake by human platelets. Eur J Pharmacol 1993; 245: 67-73.
72. Barradas MA, Jagroop A, O'Donoghue S, Jeremy JY, Mikhailidis DP. Effect of milrinone in human platelet shape change, aggregation and thromboxane A2 synthesis: an in vitro study. Thromb Res 1993; 71: 227-36.